2023 HRS/APHRS/LAHRS Guideline on Cardiac Physiologic Pacing for the Avoidance and Mitigation of Heart Failure
Authors, Journal, Affiliations, Type, DOI
- Chair: Mina K. Chung, MD, FHRS (Cleveland Clinic); HRS Vice-Chair: Kristen K. Patton; APHRS Vice-Chair: Chu-Pak Lau; LAHRS Vice-Chair: Alexander R. J. Dal Forno
- Writing committee: a large multinational committee from 15 countries, including a patient partner and representatives of HFSA, AHA, ACC, PACES, ISHNE, APHRS and LAHRS
- Journal: Heart Rhythm, September 2023;20(9):e17–e91; co-published in the Journal of Arrhythmia
- Sponsors: Heart Rhythm Society, in partnership with the Asia Pacific Heart Rhythm Society and the Latin American Heart Rhythm Society; endorsed by the American College of Cardiology, American Heart Association, Heart Failure Society of America, International Society for Holter and Noninvasive Electrocardiology and the Pediatric and Congenital Electrophysiology Society
- Type: Clinical practice guideline — the first dedicated guideline on cardiac physiologic pacing (CPP). Supersedes the pacing-indication portions of the 2012 EHRA/HRS CRT consensus and extends the 2018 ACC/AHA/HRS bradycardia guideline
- DOI: https://doi.org/10.1016/j.hrthm.2023.03.1538
Overview
This guideline defines cardiac physiologic pacing (CPP) as any pacing intended to restore or preserve ventricular synchrony, an umbrella covering coronary-sinus or epicardial cardiac resynchronization therapy (CRT) and conduction system pacing (CSP) — His bundle pacing (HBP) and left bundle branch area pacing (LBBAP). It is the first document to place all three strategies on one recommendation scale, and its central finding is a hierarchy of evidence rather than of physiology: CRT rests on multiple randomised trials with mortality benefit, whereas the CSP evidence is overwhelmingly observational, so CSP is offered as an alternative at COR 2a or 2b and never at COR 1 for a heart-failure indication. The guideline delivers 73 recommendations across indications, pre-procedure evaluation, implantation, follow-up and congenital/pediatric populations, with a mean consensus of 97.3% and 32 recommendations at 100%. Its most consequential new content is a quantified definition of "substantial" right ventricular pacing (20%–40%), COR 2b clearance for LBBAP in normal left ventricular ejection fraction, and COR 1 status for CRT in women at QRS 120–149 ms.
Keywords
Guideline · Cardiac resynchronization therapy · Conduction system pacing · His bundle pacing · Left bundle branch area pacing · Cardiac physiologic pacing · Pacing-induced cardiomyopathy · Heart failure
Key Takeaways
Top 10 Take-Home Messages
- CPP is any pacing that restores or preserves ventricular synchrony, achieved either by engaging the intrinsic conduction system (CSP: HBP or LBBAP) or by CRT, most often biventricular pacing through a coronary sinus branch.
- The evidence for CRT is substantially stronger than for CSP. Multiple randomised trials show CRT reduces symptoms, heart failure hospitalisation, improves left ventricular function and increases survival; most CSP data are observational and long-term lead survival data are lacking.
- "Response" has no consensus definition and may mean improved mortality or hospitalisation, improved clinical parameters, stabilised ventricular function, or simply prevention of progression.
- Periodic assessment of ventricular function is recommended for patients requiring substantial right ventricular pacing, or with chronic left bundle branch block (LBBB), to detect pacing- or dyssynchrony-induced cardiomyopathy.
- Patients expected to need substantial ventricular pacing may be considered for CPP to reduce the risk of pacing-induced cardiomyopathy.
- Patients with left ventricular ejection fraction (LVEF) 35%–50% expected to need less than substantial pacing may not benefit sizeably from CPP — conventional right ventricular lead placement with pacing minimisation, CSP and CRT in the presence of LBBB are all acceptable.
- LBBAP receives new recommendations at COR 2b for patients with normal LVEF who need a pacing device.
- CRT remains COR 1 for heart failure with LVEF ≤35%, LBBB, QRS ≥150 ms and NYHA class II–IV on guideline-directed medical therapy; CSP is COR 2a only when effective CRT cannot be achieved, and CRT is now COR 1 for select characteristics (eg, female sex) at QRS 120–149 ms.
- New CPP recommendations cover non-LBBB with LVEF ≤35% at both QRS <150 and ≥150 ms, at COR 2b.
- Electrocardiographic demonstration of biventricular capture (CRT) or conduction system capture (CSP) is essential during implantation and at follow-up.
Definitions
| Term |
Definition |
| LBBB |
QRS ≥120 ms with a broad notched or slurred R wave in leads I, aVL, V5 and V6, per the 2009 AHA/ACCF/HRS ECG standardisation statement |
| CPP |
Any cardiac pacing intended to restore or preserve ventricular synchrony, by CSP or CRT |
| CSP |
Recruitment of the intrinsic conduction system by HBP or LBBAP |
| HBP |
Direct stimulation of the His bundle; selective (His only) or nonselective (His plus local septal myocardium) |
| LBBAP |
Ventricular pacing intended to engage all or part of the left bundle fascicular system; selective LBB pacing, nonselective LBBAP, or deep septal pacing with no direct left bundle recruitment |
| CRT |
Left ventricular stimulation timed to right ventricular sensing or pacing, most commonly biventricular pacing; for this guideline CRT means biventricular or LV pacing, not CSP |
| Substantial RVP |
Documented or anticipated right ventricular pacing of ≥20%–40%; less than substantial means <20%–40% |
- The 20%–40% band is deliberately a range, not a threshold. The older 40% figure came from observational data, but several studies suggest pacing above 20% is already detrimental and the pre-implant burden cannot be predicted accurately.
- Response criteria (Table 5) are clinical (mortality, heart failure hospitalisation, NYHA class, quality of life, peak oxygen uptake, 6-minute walk distance, diuretic reduction) and echocardiographic (LVEF improvement or stability, reduced LV size, increased stroke volume, reduced mitral regurgitation).
Detection of Dyssynchrony-Induced Cardiomyopathy
| Recommendation |
COR |
LOE |
| Periodic assessment of ventricular function in patients with substantial right ventricular pacing that cannot be minimised by programming, to detect pacing-induced cardiomyopathy |
1 |
B-NR |
| Periodic assessment of ventricular function in patients with chronic LBBB |
2a |
B-NR |
- Pacing-induced cardiomyopathy is common and reversible. A systematic review of 26 studies and nearly 58,000 patients found a pooled prevalence of 12%, using 15 different definitions across 23 publications; reported incidence ranges 5.9%–39% over 0.7–16 years.
- Suggested surveillance interval is every 1–2 years, with a reduced frequency once stable; high-risk features are baseline QRS >115 ms and paced QRS >150 ms.
- LBBB prevalence is 0.2%–1.1% in the general population, and about 30% of dilated cardiomyopathy patients have an interventricular conduction delay, most often LBBB — but not all LBBB causes cardiomyopathy, and there is no consensus definition of LBBB-mediated cardiomyopathy.
Pacemaker Indications — Substantial Ventricular Pacing
Applies to patients with a bradycardia pacing indication, not those with a pre-existing heart-failure indication.
| Recommendation |
COR |
LOE |
| LVEF 36%–50% with anticipated substantial ventricular pacing: CPP is reasonable to reduce pacing-induced cardiomyopathy |
2a |
B-R (CRT); B-NR (HBP, LBBAP) |
| Normal LVEF with anticipated substantial ventricular pacing: CPP may be reasonable to reduce pacing-induced cardiomyopathy |
2b |
B-NR |
| Ventricular pacing–dependent patient undergoing HBP pacemaker implantation: an additional backup lead may be reasonable |
2b |
C-LD |
- The backup-lead recommendation is specific to HBP, because His leads carry a 5%–7% medium-term revision rate from rising capture threshold, dislodgement, loss of capture or atrial/His oversensing; LBBAP lead stability resembles conventional right ventricular pacing.
- Supporting evidence: HBP versus right ventricular pacing showed fewer heart failure hospitalisations (2% vs 15%) and lower composite death/heart failure/upgrade (25% vs 32%, HR 0.71); an LBBAP registry of 703 patients showed the composite outcome at 10.0% versus 23.3% (HR 0.46), driven by patients pacing >20%.
Pacemaker Indications — Less Than Substantial Ventricular Pacing
| Recommendation |
COR |
LOE |
| LVEF >35% with anticipated less than substantial pacing: traditional RV lead placement with minimisation of right ventricular pacing is reasonable |
2a |
B-R |
| LVEF 36%–50%: a CSP lead with HBP or LBBAP may be considered as an alternative to an RV lead |
2b |
C-LD |
| LVEF 36%–50% with LBBB: CPP may be considered to improve symptoms and LVEF |
2b |
C-LD |
| Normal LVEF: an LBBAP lead may be considered as an alternative to an RV lead |
2b |
C-LD |
| Normal LVEF with anticipated less than substantial pacing: CRT with biventricular pacing is not indicated |
3: No Benefit |
B-R |
- The evidence for CSP benefit is confined to patients who pace substantially. When pacing burden is minimal, comparative studies show no clinical difference between CSP and right ventricular pacing.
- The one positive signal at low burden is LBBB with mildly reduced LVEF, where observational studies show improved symptoms and LVEF.
At the Time of Cardiac Surgery
| Recommendation |
COR |
LOE |
| Patients undergoing cardiac surgery who will likely require future CRT: intraoperative permanent epicardial LV lead can be useful |
2a |
B-R |
| Patients who will likely require substantial ventricular pacing: intraoperative permanent epicardial LV lead may be considered to reduce pacing-induced cardiomyopathy |
2b |
C-EO |
- RESCUE randomised 178 patients with LVEF ≤35%, NYHA III–IV and QRS >120 ms or echocardiographic dyssynchrony to CABG with epicardial CRT versus CABG alone: all-cause mortality HR 0.43 and readmission 9.9% vs 28.7% at 55 months.
- A caveat the guideline states plainly: an epicardial LV lead left unconnected to a generator may preclude future magnetic resonance imaging at many institutions.
Heart Failure with LBBB, QRS ≥150 ms
| Recommendation |
COR |
LOE |
| LVEF ≤35%, sinus rhythm, LBBB, QRS ≥150 ms, NYHA II–IV on GDMT: CRT with biventricular pacing is indicated to improve symptoms and reduce morbidity and mortality |
1 |
A |
| Same population: CSP with HBP with LBBB correction or LBBAP is reasonable if effective CRT cannot be achieved with biventricular pacing on anatomical or functional grounds |
2a |
C-LD |
| LVEF ≤30%, LBBB, QRS ≥150 ms, NYHA I on GDMT: CRT with biventricular pacing may be considered |
2b |
B-R |
| LVEF 36%–50%, LBBB, QRS ≥150 ms, NYHA II–IV on GDMT: CPP may be considered to maintain or improve LVEF |
2b |
C-LD |
| LVEF ≤35%, LBBB, QRS ≥150 ms, NYHA II–IV on GDMT: CSP with HBP or LBBAP may be considered as an alternative to CRT |
2b |
C-LD |
- Why CSP is downgraded relative to CRT: HBP corrects LBBB in 70%–90% of cases, but LBBAP has no randomised outcome trial and long-term lead survival data are lacking. The LBBAP Collaborative cohort reported 85% implant success with stable thresholds at 6 months.
- An HBP lead in a defibrillator must not be used for tachycardia detection, because small R waves and atrial oversensing can cause inappropriate shocks or failure to treat ventricular arrhythmia.
Heart Failure with LBBB, QRS 120–149 ms
| Recommendation |
COR |
LOE |
| Select characteristics (eg, female sex), LVEF ≤35%, LBBB, QRS 120–149 ms, NYHA II–IV on GDMT: CRT is recommended to reduce mortality and heart failure events and improve LVEF |
1 |
A |
| LVEF ≤35%, LBBB, QRS 120–149 ms, NYHA II–IV on GDMT: CRT is reasonable |
2a |
B-R |
- This is the guideline's clearest use of a phenotype as an effect modifier. Women derive CRT benefit at narrower QRS durations, with relative risk reductions of 85% at 130–139 ms and 69% at 140–149 ms — no significant benefit in men at those durations.
- Height, not sex, may be the operative variable: a meta-analysis found shorter stature conferred greater CRT benefit, with a hazard ratio below 0.8 at QRS 120 ms for height <152 cm, 135 ms for <165 cm and 149 ms for <181 cm.
- No CSP recommendation is made in this band, because the evidence for HBP and LBBAP here is extremely limited.
Heart Failure with Non-LBBB
| Recommendation |
COR |
LOE |
| LVEF ≤35%, non-LBBB, QRS ≥150 ms, NYHA III or ambulatory IV on GDMT: CRT can be useful to improve functional class, structure and LVEF |
2a |
A |
| LVEF ≤35%, non-LBBB, QRS ≥150 ms, NYHA II on GDMT: CPP may be considered |
2b |
B-R (CRT); C-LD (HBP, LBBAP) |
| LVEF ≤35%, non-LBBB, QRS ≥150 ms, NYHA II–IV on GDMT: CSP may be reasonable if effective CRT cannot be achieved |
2b |
C-LD |
| LVEF ≤35%, non-LBBB, QRS 120–149 ms, NYHA III–IV on GDMT: usefulness of CPP is not well established |
2b |
B-NR (CRT); C-LD (HBP, LBBAP) |
| LVEF ≤35%, NYHA II–IV on GDMT, QRS <120 ms: CRT is not recommended |
3: No Benefit |
B-R |
| LVEF ≤35%, non-LBBB, QRS <150 ms, NYHA I–II on GDMT: CRT is not recommended |
3: No Benefit |
B-R |
- The rationale is anatomical. A prolonged LBBB usually reflects conduction-system delay with latest activation in the posterolateral LV, which pacing can correct; a shorter non-LBBB abnormality reflects intrinsic myocardial disease or variable sites of delay, which it cannot.
- RBBB is the weakest substrate of all: real-world data show benefit of CRT in intraventricular conduction delay with QRS ≥150 ms but not in RBBB with QRS ≥150 ms.
Pacing-Induced Cardiomyopathy with High-Burden Right Ventricular Pacing
| Recommendation |
COR |
LOE |
| Declining LV function or worsening heart failure attributed to substantial ventricular pacing: CRT with biventricular pacing is recommended |
1 |
B-NR |
| Same population: revision of the device to a CSP system can be beneficial |
2a |
B-NR |
- Typical PICM criteria in the cited studies: a ≥10% fall in LVEF from a baseline above 50%, pacing ≥20%, and no alternative explanation.
- Upgrading to HBP restored LVEF from 34.3% to 48.2% in a 60-patient multicentre series (95% implant success); LBBAP upgrade raised LVEF from 36.3% to 51.9% in 19 of 20 patients.
- There are no randomised trials of upgrade to CSP for PICM, which is why it sits at 2a rather than 1.
Pacing in Atrial Fibrillation
| Recommendation |
COR |
LOE |
| AF undergoing atrioventricular junction (AVJ) ablation with LVEF ≤50%: CRT is reasonable to improve heart failure hospitalisation, reverse remodelling, quality of life, exercise capacity, LVEF and potentially mortality |
2a |
B-R |
| AF otherwise meeting CRT eligibility: CRT can be beneficial |
2a |
B-NR |
| AF undergoing AVJ ablation: HBP with or without a backup ventricular lead may be reasonable |
2b |
C-LD |
| AVJ ablation: it may be reasonable to implant an LBBAP lead |
2b |
C-LD |
| High burden of ventricular pacing: HBP or LBBAP may be reasonable to decrease the risk of AF |
2b |
C-LD |
- A very high biventricular pacing percentage is essential in AF — close to 100%. A biventricular pacing percentage above 92% was associated with a 44% reduction in clinical events versus 92% or less.
- APAF-CRT established AVJ ablation plus CRT as superior to pharmacological rate control, including a mortality benefit in the mortality phase (n=133) irrespective of baseline LVEF.
Survival Less Than One Year
- COR 1, C-EO: in patients with a life expectancy under one year, the decision to implant a CPP device should incorporate shared decision-making, balancing potential quality-of-life improvement against procedural risk.
- Most trials excluded non-cardiac mortality under one year, so this is expert opinion only.
Combination CRT (LV Lead plus HBP or LBBAP)
- No recommendations were made. The writing committee reached consensus that the evidence is insufficient, and all supporting studies are uncontrolled observational series.
- Reported results: CRT plus HBP (n=27) narrowed QRS from 183 ms to 120 ms and raised LVEF from 24% to 38%; CRT plus LBBAP (n=112, 81% implant success) narrowed QRS from 182 ms to 144 ms and raised LVEF from 28.7% to 37%, with clinical improvement in 76%.
- See concepts/LOT-CRT for the wider observational evidence base.
Pre-Procedure Evaluation
| Recommendation |
COR |
LOE |
| 12-lead ECG to evaluate rhythm, rate, atrioventricular conduction, and QRS duration and morphology to determine the type of CPP |
1 |
A |
| Pre-procedural echocardiographic screening for LVEF |
1 |
A (CRT); C-EO (HBP, LBBAP) |
| Imaging (echocardiography, cardiac MRI or CT) to target LV lead placement in CRT |
2b |
B-R |
| Pre-procedural echocardiographic assessment of ventricular dyssynchrony to predict CRT outcome |
3: No Benefit |
A |
| Shared decision-making covering the evidence base, goals of care, preferences, battery longevity, future lead management and end-of-life considerations |
1 |
C-EO |
- The ECG remains the selection standard despite its limitations, and mechanical dyssynchrony measures have repeatedly failed in multicentre prospective trials — the PROSPECT study tested 12 echocardiographic parameters and none improved selection.
Implant Technique — CRT with Biventricular Pacing
| Recommendation |
COR |
LOE |
| Quadripolar LV lead |
1 |
B-R |
| Lead positioning and programming to deliver the narrowest QRS duration |
2a |
B-NR |
| LV lead placement allowing a non-apical position |
2a |
C-LD |
| Targeting sites of late ventricular activation |
2b |
C-LD |
- QLV (QRS onset to local LV electrogram) above 95 ms, or above 50% of the QRS duration, favours response; QLV above 120 ms improves the chance further.
Implant Technique — Conduction System Pacing
| Recommendation |
COR |
LOE |
| 12-lead ECG during implantation to assess conduction system capture |
1 |
C-EO |
| Demonstration of conduction system capture thresholds (including bundle branch block correction) and myocardial capture thresholds at implant |
1 |
C-EO |
| Assessment of His bundle or left bundle current of injury using appropriate filter settings |
2a |
C-LD |
- Injury current predicts stable thresholds: all 115 LBBAP patients with left bundle injury current had thresholds below 1.5 V at 0.5 ms, versus 76% without.
- His capture thresholds should be below 2.5 V at 1 ms at implant, and automatic threshold-assessment algorithms should be turned off for HBP.
- Pacing at ≥120 beats/min is used to confirm distal conduction system capture during CSP for infranodal block.
Intraprocedural Crossovers
| Recommendation |
COR |
LOE |
| Coronary sinus LV lead placement unsuccessful or suboptimal: crossover to CSP with HBP or LBBAP is reasonable |
2a |
C-LD |
| Initial approach unsuccessful or suboptimal: crossover to surgical epicardial CRT might be reasonable |
2b |
C-LD |
- Failure rates: LV lead placement fails in up to 10% of CRT implants; HBP or LBBAP implantation fails in 10%–40%.
- Criteria for abandoning an approach are not standardised and remain operator-dependent.
Follow-Up
| Recommendation |
COR |
LOE |
| Follow-up echocardiogram within 3–12 months after implantation in HFrEF |
1 |
B-NR (CRT); C-EO (HBP, LBBAP) |
| Remote monitoring |
1 |
B-NR |
| Multidisciplinary management with heart failure and device clinics |
2a |
B-NR (CRT); C-EO (HBP, LBBAP) |
| Continuation of guideline-directed medical therapy in heart failure with improved ejection fraction |
2a |
C-LD |
| Routine use of thoracic impedance alone to manage congestive heart failure |
3: No Benefit |
B-R |
- Every 10% decrease in LV end-diastolic volume or 5-point LVEF increase was associated with a 40% reduction in death or heart failure hospitalisation in MADIT-CRT.
- During in-office CSP follow-up (COR 1, B-NR), a multilead or 12-lead ECG is recommended to document conduction system capture including bundle branch block correction; comprehensive threshold documentation is COR 2a.
- A His capture threshold rise above 1 V warrants more frequent follow-up (COR 2a, C-EO), because late threshold rise occurred in 15% of 294 HBP patients, mostly within 8 weeks.
Generator Replacement and Troubleshooting
| Recommendation |
COR |
LOE |
| Heart failure with improved ejection fraction: continuation of CRT at elective replacement |
1 |
C-LD |
| Patient thought to have benefited from CRT (improvement, stabilisation or partial reversal of decline): continuation of CRT at elective replacement |
1 |
C-EO |
| CRT-D at elective replacement: decide replacement versus revision to CRT-P by individualised risk–benefit and shared decision-making |
1 |
B-NR |
| High lead pacing threshold contributing to rapid battery drain: a new lead may be considered at generator replacement |
2b |
C-EO |
| Unfavourable response to CRT: continued optimisation of medical and device therapy |
1 |
C-LD |
| Unfavourable response: posteroanterior and lateral chest X-ray to assess LV lead position |
1 |
C-LD |
| Unfavourable response with suboptimal LV pacing percentage: ablation or pharmacological suppression of frequent PVCs, or better rhythm/rate control of AF |
2a |
C-LD |
| Suboptimal response to CRT: CSP or surgical epicardial lead implantation can be useful when other approaches have failed or are not feasible |
2a |
C-LD (HBP, LBBAP); B-NR (surgical epicardial) |
- The "non-responder" label is contested. The guideline prefers "favorable responder" (including the stabiliser or non-progressor, whose decline is blunted rather than reversed) and "unfavorable responder".
- Inappropriate ICD deactivation is not endorsed: the risk of ventricular tachyarrhythmia persists after LVEF improvement, even when near-normal, so continuation of defibrillator therapy is recommended.
Congenital Heart Disease
| Recommendation |
COR |
LOE |
| CHD, systemic LV, on GDMT, LVEF <45%, ventricular dyssynchrony (QRS z-score ≥3 or ventricular pacing ≥40%): CRT is reasonable to reduce mortality or transplant need |
2a |
C-LD |
| CHD, systemic single ventricle requiring pacing: apical pacing is reasonable in preference to non-apical |
2a |
C-LD |
| CHD, systemic single ventricle with symptomatic heart failure: CRT with multisite ventricular pacing may be considered |
2b |
C-LD |
| CHD, systemic RV with symptomatic heart failure associated with ventricular electrical delay or substantial pacing: CRT may be considered |
2b |
C-LD |
| CHD, subpulmonary RV dysfunction with RBBB: CRT with fusion-based pacing may be considered |
2b |
C-LD |
| Congenitally corrected transposition of the great arteries with AV block and no anatomic repair: CSP with HBP or LBBAP may be considered |
2b |
C-LD |
- QRS duration must be normalised for age with a z-score in children, because normal QRS changes with growth.
- Surgical heart block occurs in 1%–6% of CHD patients, and congenitally corrected transposition carries a 2% annual risk of AV block.
Pediatric Patients Without Congenital Heart Disease
| Recommendation |
COR |
LOE |
| Complete AV block, pre-existing ventricular pacing and symptomatic heart failure on GDMT: CRT is reasonable |
2a |
C-LD |
| Complete AV block with clinical heart failure on GDMT: CPP may be considered |
2b |
C-LD |
| Pacemaker implantation for AV block: target an RV mid-septal, inflow or outflow tract transvenous site, or apical LV epicardial pacing, in preference to RV apical endocardial or epicardial pacing |
2a |
C-LD |
- About 10% of children with congenital complete AV block develop dyssynchrony and dilated cardiomyopathy.
- No recommendation is made for HBP or LBBAP in children, because the reported experience is small, thresholds are elevated and some leads required revision.
Identified Evidence Gaps
- Long-term risks and consequences of LBBAP and HBP, including lead survival and extraction.
- Clinical outcome differences between LV septal pacing and true left bundle pacing.
- Randomised trials of CSP versus right ventricular pacing in normal LVEF with substantial pacing need.
- Randomised trials in infrequent ventricular pacing.
- CRT thresholds for stature and LV size at QRS <150 ms.
- Randomised trials of CSP versus biventricular pacing in CRT-indicated patients, and of CRT plus LV lead versus CRT plus HBP or LBBAP.
- Effect of CSP on new-onset and progressive AF.
- Standardised definitions of lead placement success and failure.
Limitations of the document
- The CSP evidence base is observational or from small randomised trials without long-term follow-up, a limitation the writing committee states repeatedly and uses to justify every COR 2a/2b rating for CSP. Several CSP recommendations are expert opinion (C-EO) only.
- The document predates the major post-2023 trials. LEFT-BUNDLE-CRT, the I-CLAS cohorts and the 2025 appropriate-use criteria all post-date this guideline, so its CSP classes are already behind the observational literature.
- The 20%–40% definition of substantial pacing is an acknowledgement of uncertainty, not a measurement. The guideline concedes that pacing burden cannot be predicted accurately before implantation and that the underlying percentages come from cohorts with inconsistent definitions.
- Recommendations assume an appropriately trained operator and equipped centre, so procedural success rates quoted here reflect expert practice and may not generalise.
- The scope excludes bradycardia pacing indications themselves, ICD indications, lead extraction and cardiac contractility modulation pacing, which are addressed in other documents.
- Section 7 (congenital and pediatric) rests on small series, with variable response definitions and follow-up ranging 0.7–16 years.
- Cost, access and health-equity implications of CSP — which requires longer procedures and specialised tools — are not addressed.
Key Concepts Mentioned
Key Entities Mentioned
Wiki Pages Updated
- wiki/sources/cardiac-physiologic-pacing-hrs-2023.md (created)
- wiki/sourceindex.md (updated)
- wiki/wikiindex.md (checked — no new concept or entity rows)
- wiki/concepts/Conduction-System-Pacing.md (updated — guideline recommendations section)
- wiki/concepts/Cardiac-Resynchronization-Therapy.md (updated — 2023 HRS/APHRS/LAHRS classes)
- wiki/concepts/Pacing-Induced-Cardiomyopathy.md (updated — 20%–40% definition, surveillance, upgrade classes)
- wiki/concepts/Permanent-Pacing-Indications.md (updated — pacing-mode selection)
- wiki/concepts/LOT-CRT.md (updated — no-recommendation status)
- wiki/entities/CRT.md (updated — 2023 guideline framework)